<DOC>
	<DOC>NCT00502632</DOC>
	<brief_summary>The purpose of this study is to determine whether intrapleural treatment with Dornase alfa plus Urokinase improves clinical outcome compared to Urokinase alone in children with complicated parapneumonic effusions</brief_summary>
	<brief_title>Dornase Alfa and Urokinase for Kids With Pleural Empyema</brief_title>
	<detailed_description />
	<mesh_term>Empyema</mesh_term>
	<mesh_term>Empyema, Pleural</mesh_term>
	<criteria>Age &gt; 1 year and &lt; 16 years Respiratory infection (pneumonia or lung abscess) Effusion occupying at least 1/3 of hemithorax on chest Xray Complicated effusion (presence of at least one of the following): Hyperechoic pleural fluid on chest US scan Loculated collection on chest US or CT scan Purulent pleural fluid Positive culture or Gram stain on pleural fluid Non parapneumonic effusion Immunodeficiency Neurological impairment Suspected or proven allergy to Urokinase or Dornase alfa Suspected or documented bronchopleural fistula Impaired coagulation (INR&gt;2), haemorrhage, high risk for bleeding Thoracic surgical procedure (e.g. thoracoscopy, minithoracotomy) already performed Chest drain inserted since 6 or more days</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Pleural empyema</keyword>
	<keyword>Pleural effusion</keyword>
	<keyword>Dornase alfa</keyword>
	<keyword>Urokinase</keyword>
	<keyword>Children</keyword>
</DOC>